JP2024535872A5 - - Google Patents
Info
- Publication number
- JP2024535872A5 JP2024535872A5 JP2024517113A JP2024517113A JP2024535872A5 JP 2024535872 A5 JP2024535872 A5 JP 2024535872A5 JP 2024517113 A JP2024517113 A JP 2024517113A JP 2024517113 A JP2024517113 A JP 2024517113A JP 2024535872 A5 JP2024535872 A5 JP 2024535872A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- recombinant nucleic
- acid molecule
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245661P | 2021-09-17 | 2021-09-17 | |
| US63/245,661 | 2021-09-17 | ||
| PCT/US2022/076612 WO2023044457A1 (en) | 2021-09-17 | 2022-09-16 | Switch receptors using il-9 signaling domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535872A JP2024535872A (ja) | 2024-10-02 |
| JP2024535872A5 true JP2024535872A5 (cg-RX-API-DMAC7.html) | 2025-09-25 |
Family
ID=83688655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517052A Pending JP2024535868A (ja) | 2021-09-17 | 2022-09-16 | Il-9シグナル伝達ドメインを使用したスイッチ受容体 |
| JP2024517113A Pending JP2024535872A (ja) | 2021-09-17 | 2022-09-16 | Il-9シグナル伝達ドメインを使用したスイッチ受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517052A Pending JP2024535868A (ja) | 2021-09-17 | 2022-09-16 | Il-9シグナル伝達ドメインを使用したスイッチ受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US12202884B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4402161A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024535868A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118251410A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022347445A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3232664A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023044457A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12291651B2 (en) | 2021-04-07 | 2025-05-06 | Wisconsin Alumni Research Foundation | Liquid crystal-infused slippery anti-fouling surfaces |
| CA3231615A1 (en) * | 2021-09-17 | 2023-03-23 | Mikko SIURALA | Chimeric antigen receptors comprising interleukin-9 receptor signaling domain |
| EP4402161A1 (en) | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2024019984A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cytokine receptor switch polypeptides and uses thereof |
| WO2025039159A1 (en) * | 2023-08-21 | 2025-02-27 | Hangzhou Hervor Therapeutics Co., Ltd | Synthetic cytokine signaling system, preparation method, and uses thereof |
| WO2025117789A1 (en) * | 2023-12-01 | 2025-06-05 | Parker Institute For Cancer Immunotherapy | Engineered immune signaling constructs |
| WO2026024685A1 (en) * | 2024-07-23 | 2026-01-29 | Feromics Inc. | Uses of immunomodulatory fusion proteins to enhance efficacy of car-expressing immune effector cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO2010006111A2 (en) | 2008-07-10 | 2010-01-14 | Merck & Co., Inc. | Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| GB201514875D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| JP7299021B2 (ja) | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン/受容体ペア |
| AU2016374497B2 (en) | 2015-12-16 | 2022-03-10 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced SH2 protein in NK cells |
| CN109880803B (zh) * | 2017-12-06 | 2024-06-07 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN110615843B (zh) | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| JP2020110135A (ja) | 2019-01-09 | 2020-07-27 | エーテーハー チューリッヒEth Zurich | 汎用細胞外分子センサー |
| JP2022519704A (ja) | 2019-02-08 | 2022-03-24 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | キメラサイトカイン受容体 |
| GB201911187D0 (en) * | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| WO2021141986A1 (en) | 2020-01-07 | 2021-07-15 | St. Jude Children's Research Hospital, Inc. | Chimeric gmcsf-il18 receptor |
| US20230138428A1 (en) * | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| JP2023520572A (ja) | 2020-04-06 | 2023-05-17 | シンセカイン インコーポレイテッド | オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞 |
| EP4305054A4 (en) | 2021-03-09 | 2025-03-19 | The Trustees of The University of Pennsylvania | SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2 |
| EP4082429A1 (en) * | 2021-04-28 | 2022-11-02 | Koninklijke Philips N.V. | A shell cuff |
| US11688614B2 (en) * | 2021-04-28 | 2023-06-27 | Kla Corporation | Mitigating thermal expansion mismatch in temperature probe construction apparatus and method |
| CA3231615A1 (en) | 2021-09-17 | 2023-03-23 | Mikko SIURALA | Chimeric antigen receptors comprising interleukin-9 receptor signaling domain |
| EP4402161A1 (en) | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| EP4554972A1 (en) | 2022-07-11 | 2025-05-21 | The Board of Trustees of the Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
-
2022
- 2022-09-16 EP EP22786722.3A patent/EP4402161A1/en active Pending
- 2022-09-16 AU AU2022347445A patent/AU2022347445A1/en active Pending
- 2022-09-16 CA CA3232664A patent/CA3232664A1/en active Pending
- 2022-09-16 JP JP2024517052A patent/JP2024535868A/ja active Pending
- 2022-09-16 EP EP22786723.1A patent/EP4402162A2/en active Pending
- 2022-09-16 CA CA3232668A patent/CA3232668A1/en active Pending
- 2022-09-16 CN CN202280074481.3A patent/CN118251410A/zh active Pending
- 2022-09-16 JP JP2024517113A patent/JP2024535872A/ja active Pending
- 2022-09-16 CN CN202280074174.5A patent/CN118234746A/zh active Pending
- 2022-09-16 US US17/946,916 patent/US12202884B2/en active Active
- 2022-09-16 WO PCT/US2022/076612 patent/WO2023044457A1/en not_active Ceased
- 2022-09-16 WO PCT/US2022/076618 patent/WO2023044461A2/en not_active Ceased
- 2022-09-16 US US17/946,894 patent/US20230110313A1/en not_active Abandoned
- 2022-09-16 AU AU2022348588A patent/AU2022348588A1/en active Pending
-
2023
- 2023-06-02 US US18/328,473 patent/US12221469B2/en active Active
-
2024
- 2024-12-09 US US18/974,281 patent/US20250179148A1/en active Pending
- 2024-12-27 US US19/003,599 patent/US20250136664A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024535868A5 (cg-RX-API-DMAC7.html) | ||
| US20210380701A1 (en) | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES | |
| JP7750929B2 (ja) | 単鎖キメラポリペプチドおよびその使用 | |
| JP2022536347A5 (cg-RX-API-DMAC7.html) | ||
| Ho et al. | A receptor for interleukin 10 is related to interferon receptors. | |
| US20240181009A1 (en) | Synthekine compositions and methods of use | |
| JP7023709B2 (ja) | 抗炎症特性を有するペプチド | |
| TWI713798B (zh) | 增加介白素-2(il-2)分泌量之方法和源自該方法之蛋白類 | |
| JP2022505663A5 (cg-RX-API-DMAC7.html) | ||
| JP6947642B2 (ja) | 抗がん性融合ポリペプチド | |
| Dinarello | Targeting interleukin 18 with interleukin 18 binding protein | |
| US10040841B2 (en) | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof | |
| RS51157B (sr) | Baff receptor (bcma), imunoregulatorni agens | |
| KR20180054713A (ko) | 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법 | |
| JP2021527700A5 (cg-RX-API-DMAC7.html) | ||
| US20220119478A1 (en) | Advanced chimeric antigen receptor vectors for targeting solid tumors | |
| KR20200138741A (ko) | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 | |
| JP2023542312A5 (cg-RX-API-DMAC7.html) | ||
| JP2022544785A (ja) | 改変インターロイキン2受容体ベータアゴニスト | |
| WO2018132572A1 (en) | R-spondin (rspo) surrogate molecules | |
| WO2018229492A1 (en) | Chimeric antigen receptor | |
| JP2005514061A (ja) | 組換えポリペプチド | |
| Guo et al. | Chimeric non-antigen receptors in T cell-based cancer therapy | |
| KR20230020443A (ko) | 4-1bb 표적화 다량체 면역조절제 | |
| Moosmayer et al. | Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity |